1417333-22-2

Basic information

• Product Name: 1-(4-methoxyphenyl)-3-methyl-1H-pyrazolo[3,4-b]pyridin-4-ol
• Synonyms: 1-(4-methoxyphenyl)-3-methyl-1H-pyrazolo[3,4-b]pyridin-4-ol
• CAS NO: 1417333-22-2
• Molecular Weight: 255.276
• Mol File: 1417333-22-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-(4-methoxyphenyl)-3-methyl-1H-pyrazolo[3,4-b]pyridin-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-methoxyphenyl)-3-methyl-1H-pyrazolo[3,4-b]pyridin-4-ol(1417333-22-2)
• EPA Substance Registry System: 1-(4-methoxyphenyl)-3-methyl-1H-pyrazolo[3,4-b]pyridin-4-ol(1417333-22-2)

Safety Data

• Hazardous Substances Data: 1417333-22-2(Hazardous Substances Data)

Usage

Class

Benzimidazole-pyrazolopyridine

Medicinal Use

Treatment of congestive heart failure and certain types of heart disease in dogs

Mechanism of Action

Increases the strength of the heart muscle and opens up blood vessels in the lungs

Effectiveness

Improves heart function and reduces clinical signs of heart failure in dogs

Application

Valuable tool in the treatment of cardiac diseases in veterinary medicine

Upstream product

• 3471-32-7 4-Methoxyphenylhydrazine 
• 1417333-21-1 4-hydroxy-1-(4-methoxyphenyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 
• 1027842-11-0 4-chloro-1-(4-methoxyphenyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester 
• 1025877-49-9 2-{[2-(4-methoxyphenyl)-5-methyl-2H-pyrazol-3-ylamino]methylene}malonic acid diethyl ester 
• 91331-86-1 2-(4-methoxyphenyl)-5-methyl-2H-pyrazol-3-ylamine 

Downstream Products

• 1417333-23-3 4-bromo-1-(4-methoxyphenyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine 
• 1417333-24-4 1-(4-methoxyphenyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-4-carbonitrile 
• 1417333-20-0 1-(4-methoxyphenyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-4-carbonitrile 

Relevant articles and documents

Identification, design and synthesis of novel pyrazolopyridine influenza virus nonstructural protein 1 antagonists

Nonstructural protein 1 (NS1) plays a crucial function in the replication, spread, and pathogenesis of influenza virus by inhibiting the host innate immune response. Here we report the discovery and optimization of novel pyrazolopyridine NS1 antagonists that can potently inhibit influenza A/PR/8/34 replication in MDCK cells, rescue MDCK cells from cytopathic effects of seasonal influenza A strains, reverse NS1-dependent inhibition of IFN-β gene expression, and suppress the slow growth phenotype in NS1-expressing yeast. These pyrazolopyridines will enable researchers to investigate NS1 function during infection and how antagonists can be utilized in the next generation of treatments for influenza infection.

PYRAZOLOPYRIDINES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM

The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said com- pounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine α7 receptor.